Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Aegerion Pharmaceuticals



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.6%. By the end of trading, Aegerion Pharmaceuticals rose $3.49 (5.0%) to $72.83 on heavy volume. Throughout the day, 1,662,066 shares of Aegerion Pharmaceuticals exchanged hands as compared to its average daily volume of 666,100 shares. The stock ranged in a price between $72.19-$75.17 after having opened the day at $72.76 as compared to the previous trading day's close of $69.34. Other companies within the Health Care sector that increased today were:




), up 32.5%,




), up 18.8%,

MGC Diagnostics



), up 12.9% and




), up 10.7%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States. Aegerion Pharmaceuticals has a market cap of $2.0 billion and is part of the drugs industry. Shares are up 173.0% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Aegerion Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Aegerion Pharmaceuticals as a


. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share.

On the negative front,

Escalon Medical Corporation



), down 12.5%,

Bovie Medical Corporation



), down 11.7%,

Astex Pharmaceuticals



), down 10.2% and

AMAG Pharmaceuticals



), down 9.9% , were all laggards within the health care sector with




) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.